Microglia show a rich repertoire of activation patterns regulated by a complex ensemble of surface ion channels, receptors, and transporters. We and others have investigated whether microglia vary their K 1 channel expression as a means to achieve functional diversity. However, most of the prior studies were conducted using in vitro models such as BV2 cells, primary microglia, or brain slices in anti-inflammatory and hLTP-recovery effects similar to Kv1.3 knockout. We conclude that Kv1.3 is required for microglial M1-like pro-inflammatory activation in vivo. A significant implication of our in vivo data is that Kv1.3 blockers could be therapeutic candidates for neurological diseases where microglia-mediated neurotoxicity is implicated in the pathogenesis.
K 1 channels are encoded by a super-family of 78 genes (Harmar et al., 2009) and are involved in diverse physiological and pathological processes. K 1 channels accordingly already serve as drug targets for cardiac arrhythmia and Type-2 diabetes and have been proposed as targets for immunosuppression, cancer and various neurological disorders (Wulff, Castle, & Pardo, 2009 ). The voltage-gated Kv1.3 channel is expressed in T lymphocytes, macrophages and microglia and has been suggested as a novel target for immunomodulation in autoimmune diseases such as multiple sclerosis, Type-1 diabetes, and psoriasis (Beeton et al., 2006; Arnoux et al., 2013; Kundu-Raychaudhuri, Chen, Wulff, & Raychaudhuri, 2014; Visentin, Renzi, & Levi, 2001 ). Kv1.3 plays an important role in immune cell activation by modulating Ca 21 signaling (Feske, Wulff, & Skolnik, 2015; Wulff et al., 2007) . Through K 1 efflux, Kv1.3 helps maintain a negative membrane potential, which provides the driving force for Ca 21 entry through store-operated inward-rectifier calcium channels like the Ca 21 release activated Ca 21 channel ORAI or transient receptor potential cation channels. We previously demonstrated that cultured primary microglia activated by lipopolysaccharides (LPS), which induces a classic M1-like activation state, exhibited high Kv1.3 current densities but virtually no activities of the other major microglial K 1 channel, the inward-rectifier Kir2.1 . A systems pharmacology-based study identified functional roles for Kv1.3 in pro-inflammatory microglial activation (Rangaraju et al., 2017) while electrophysiological studies by our group demonstrated upregulated Kv1.3 expression in microglia acutely isolated from the infarct areas of mice subjected to experimental stroke (Chen et al., 2016) . Kv1.3 blockers have further been demonstrated to inhibit microglia mediated neurotoxicity in culture (Fordyce, Jagasia, Zhu, & Schlichter, 2005) and to protect mice from microglia mediated radiation-induced brain injury (Peng et al., 2014) .
Although Kv1.3 appears to be a suitable target for microglia-targeted modulation, a definite in vivo demonstration of the role of Kv1.3 in neuroinflammation is missing, as nearly all prior studies were conducted using BV2 cells, primary microglia, or brain slices in culture (Charolidi, Schilling, & Eder, 2015; Fordyce et al., 2005; Khanna, Roy, Zhu, & Schlichter, 2001; Kotecha & Schlichter, 1999; K€ ust et al., 1999; Nguyen et al., 2017; Rangaraju et al., 2017; Schilling & Eder, 2003; Schilling & Eder, 2011) . It is now realized that BV2 cells significantly differ from cultured or in vivo microglia in many aspects (Butovsky et al., 2014; Henn et al., 2009; Kettenmann et al., 2011) . In the widely used culture systems of microglia derived from neonatal rodents, the cells generally assume an amoeboid morphology and are highly proliferative, resembling microglia in injured tissue (Bohlen et al., 2017) . The validity of using these cultures to represent adult microglia needs to be carefully verified. Brain slice culture allows preservation of interactions between microglia, neurons, and astrocytes, but in these cultures microglia rapidly lose their characteristic ramified morphology and mature marker expression (Bohlen et al., 2017) .
The above downsides of various in vitro systems are particularly significant when ion channels such as Kv1.3 are being studied, as much of the physiological recordings in vitro are from moderately to fully activated microglial cells and do not fully represent the microglial physiology in vivo (Kettenmann et al., 2011) . For example, our previous study showed that microglia acutely isolated from normal adult mouse brains exhibited very small K 1 currents, smaller than what was observed in unstimulated cultured neonatal mouse microglia (Chen et al., 2016) . Similarly, microglia, tissue-printed from the hippocampus of 5-to 14-days old rats, were initially not proliferating and showed little Kv1.3 current. However, after several days in culture the microglia became highly proliferative and many cells exhibited a prominent Kv current that was indistinguishable from Kv1.3 (Kotecha et al., 1999) . Therefore, the in vivo significance of microglial Kv1.3 remains undetermined based on currently available literature replete with in vitro studies.
In the current study, we employed an in vivo model of selective innate immune activation by intracerebroventricular (ICV) injection of LPS (Maezawa et al., 2006) . LPS specifically activates cluster of differentiation (CD) 14/toll-like receptor (TRL) 4 co-receptors, expressed on glia and especially microglia, to induce M1-like pro-inflammatory activation. Here we report evidence supporting that Kv1.3 is required for pro-inflammatory response of microglia in vivo.
| M E T H O D S

| Mice
All protocols involving mouse models were approved by the Institutional Animal Care and Use Committee of the University of California Davis.
C57BL/6 mice were originally purchased from Jackson laboratory. The Kv1.3 2/2 (Kv1.3 KO) line on the C57BL/6 background was a gift from Dr. Leonard Kaczmarek at Yale University (Fadool et al., 2004) .
| Intracerebroventricular injection of LPS (ICV-LPS)
LPS (Escherichia coli O55:B5, Millipore, University of California Davis Medical Center, Sacramento, CA 95817, USA.) dissolved in phosphatebuffered saline (PBS) or vehicle PBS only was ICV administrated to mice stereotactically in a total volume of 2 mL per side of the ventricle.
Briefly, mice were anesthetized by 3% isoflurane and then restrained onto a stereotaxic apparatus. A small incision was made to expose the skull and a small burr hole was drilled using a surgical drill. LPS, or vehicle, was injected using a Hamilton syringe with a 27-gauge needle (Hamilton, Reno, NV) into the lateral ventricles via the coordinates:
21 mm posterior to bregma, 1.3 mm lateral to sagittal suture, and 2 mm in depth. The incision was closed using a surgical suture (Ethicon Inc, Somerville, NJ), and the mice were placed on an isothermal pad at 368C and continuously observed following surgery until recovery.
Immediately after ICV injection, mice received either an intraperitoneal injection of PAP-1 (40 mg/kg) or the vehicle (Miglyol-812, Neobee M5, Spectrum Chemicals, Gardena, CA) as control. Twenty-four hours later, mice were euthanized and the brain tissues were processed for LTP, isolation of microglia, or immunostaining. PAP-1 was synthesized in our laboratory as previously described (Schmitz et al., 2005) .
| Acute isolation of microglia from adult brains
Microglia were acutely isolated from adult brains without culturing as we described . Briefly, brains were dissociated enzymatically with a Neural Tissue Dissociation Kit (Miltenyi Biotec).
Microglia were subsequently purified by the magnetic-activated cell sorting (MACS) using anti-CD11b magnetic beads (Miltenyi Biotec).
The whole procedure took about 60 min. 
| Electrophysiology
| Induction of hippocampal long-term potentiation (hLTP) by high frequency stimulation
The preparation of mouse hippocampal slices, and the induction of hLTP by high frequency stimulation of the Schaffer collateral afferents were conducted as we previously described 
| qPCR
Total RNA from acutely isolated microglia was extracted using RNeasy Plus Mini Kit (Qiagen), reverse-transcribed and pre-amplified with Ovation PicoSL WTA System V2 kit (NuGen, San Carlos, CA). The following forward/reverse primer pairs were used:
For KCa3.1 and Kir2.1, the commercially available primer sets from Bio-Rad were used. For b-actin the commercially available primer set Mouse-ACTB from Applied Biosystems was used. Relative cDNA levels for the target genes were analyzed by the 2-DDCt method using Actb as the internal control for normalization.
| Immunofluorescence staining and quantification
Immunofluorescence staining and quantification was performed as previously described . Briefly, frozen brain sections
(20 mm) were fixed in 4% paraformaldehyde and stained with anti-Iba1 
| Tissue homogenate preparation and Western blot analysis
Brain tissues were homogenized in lysis buffer (150 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA, 1% Triton X-100, 0.5% SDS) with protease inhibitor cocktail and phosphatase inhibitor (Sigma). Equivalent amounts of protein were analyzed by 4%-15%Tris-HCl gel electrophoresis (Bio-Rad). Proteins were transferred to polyvinylidene difluoride membranes and probed with antibodies. Visualization was enabled using enhanced chemiluminescence (GE Healthcare Pharmacia). The following primary antibodies (dilutions) were used: anti-CD68 (1:1000, BioRad), anti-CD11b (1:1000, Abcam), anti-Iba1 (1:1000, Millipore),
anti-Phopspho-p38MAPK (1:1000, Cell Signaling), anti-p38MAPK
(1:1000, Cell Signaling) and b-actin (1:2000, Cell Signaling). Secondary antibodies were HRP-conjugated anti-rabbit or anti-mouse antibody
(1:1000, GE Healthcare).
| ELISA quantification
ELISA quantification of cytokines was conducted as previously described (Maezawa, Zimin, Wulff, & Jin, 2011) . Briefly, tissue sample were homogenized in lysis buffer (100 mM TRIS, pH 7.4; 150 mM NaCl; 1 mM EGTA; 1 mM EDTA; 1% Triton X-100; 0.5% Sodium deoxycholate; proteinase inhibitor mix), and centrifuged for 20 min at 15,000 rpm at 48C. The supernatants were directly used for the total cytokine (IL-1ß and TNF-a). Concentrations of IL-1ß and TNF-a were measured using the Quantikine sandwich ELISA kit (R&D systems, Minneapolis, MN).
| Statistical analysis
Paired Student's t test and two-way analysis of variance (ANOVA) with post hoc Bonferroni test, as appropriate, were conducted using the SigmaStat 3.1 (Systat Inc. Point Richmond, CA) or StatView program (version 5.0.1, SAS Institute Inc., Cary, NC). The significance level for the two-sided analysis was set at p < .05.
| R E S U LTS
| LPS increases Kv1.3 current densities on microglia in vivo
We injected 3-month-old WT and Kv1.3 KO (Kv1.3 2/2 ) mice with intracerebroventricular LPS (ICV-LPS) and 24-hr later acutely isolated microglia for whole-cell voltage-clamp and cytokine measurements.
Microglia were isolated using CD11b-based immunopanning as previously described (Bohlen et al., 2017; Jin et al., 2015) . The procedure took approximately one hour and the cells, without further culturing, were immediately used for subsequent studies. We elicited Kv currents by voltage ramps from 2120 to 140 mV as previously described Wulff et al., 2003) . In order to avoid contributions from calcium-activated K 1 channels or chloride currents we used a KFbased pipette solution. While Kv current amplitudes were very low or often barely detectable in microglia isolated from mice receiving intracerebral injection of PBS (ICV-PBS; Figure  F1  1a We quantified Kv1.3 current densities as PAP-1 sensitive outward current (for example, the difference between the black and red tracings in Figure 1b) at 140 mV. The scatterplot in Figure 1g shows that, as expected, Kv1.3 KO diminished the measurable Kv1.3 current density, in contrast to the two WT groups. ICV-LPS significantly increased Kv1.3 current densities on WT microglia, but had no effect on Kv1.3 KO microglia. Interestingly, in additional independent experiments in which cerebral cortex and hippocampus were dissected before microglia isolation, it was found that Kv1.3 was upregulated in hippocampal microglia in response to ICV-LPS, but this response was significantly less robust (p < .001) than that in cortical microglia (Figure 1h ). This result adds to previous evidence supporting location-dependent heterogeneity of microglia properties (Horiuchi, Smith, Maezawa, & Jin, 2017; McCarthy, 2017 We also detected inward rectifier current in microglia, measured as peak inward currents at 2120 mV, which were identified as Kir2.1 based on Ba 21 sensitivity and the presence of Kir2.1 message, as previously described . Consistent with our previous in vitro data , LPS stimulation in vivo did not lead to any increases in Kir2.1 current density in WT microglia ( Figure  F2  2a) . Interestingly, in contrast to WT microglia, Kv1.3 KO microglia showed a significant increase in Kir2.1 current density following ICV-LPS (Figure 2a-c) .
Quantitative PCR conducted using RNA extracted from acutely isolated microglia showed that Kv1.3 knockout did not affect the expression of other K 1 channels previously described to be expressed in microglia (Kettenmann et al., 2011 ; Figure 2d , white bars 
| Kv1.3 knockout mitigates microglial activationrelated hippocampal long-term potentiation deficits
Previous evidence demonstrates that aberrant immune processes in the brain produce detrimental effects on neuronal plasticity, FIG URE 4 LPS-induced pro-inflammatory phenotype of microglia requires Kv1.3 expression in vivo. (a) ELISA quantification of IL-1b and TNF-a levels in brain homogenates of these mice showed that increased production of the two pro-inflammatory cytokines were curbed by Kv1.3 knockout. (b) qPCR quantification of the RNA of indicated molecules showed increases of pro-inflammation cytokines and iNOS mRNA in microglia acutely isolated from WT mice at 24 hr after ICV-LPS. These increases were absent in Kv1.3KO mice. Data are presented as means 6 SEM. There are no statistical differences in all measures between Kv1.3KO/PBS and Kv1.3KO/LPS groups. RNA was isolated from WT mice receiving ICV-PBS (n 5 10) and ICV-LPS (n 5 10), and Kv1.3 KO mice receiving ICV-PBS (n 5 11) and ICV-LPS (n 5 12). Statistical analysis was performed by two-way ANOVA follow by Bonferroni correction for multiple comparisons exemplified by the reduction of hippocampal long-term potentiation (hLTP) induction and maintenance (O'Connor & Coogan, 1999; Yirmiya & Goshen, 2011) . Because pro-inflammatory microglia, especially through their increased production of TNF-a, IL-1b, and nitric oxide (NO), impair hLTP (Costello et al., 2011; Lynch, 2015; Wang, Rowan, & Anwyl, 2004) , we tested if blocking the development of the pro- 3.5 | Pharmacological inhibition of microglial Kv1.3 reduces microglial pro-inflammatory response and mitigates hLTP deficit after ICV-LPS Although published (Charolidi et al., 2015; Nguyen et al., 2017; Rangaraju, Gearing, Jin, & Levey, 2015; Rangaraju et al., 2017; Rus et al., 2005) and present data clearly showed that in the brain, Kv1.3 is mainly expressed in activated microglia, it has been described in neurons, most prominently in mitral cells of the olfactory bulb (Fadool et al., 2004) and presynaptic terminals of brain stem auditory neurons (Gazula et al., 2010) , and also in cortical interneurons and in oligodendrocyte progenitor cells but at low levels (Vautier, Belachew, Chittajallu, & Vittorio, 2004; Duque, Gazula, & Kaczmarek, 2013) , raising the possibility that the above in vivo effects of Kv1.3 knockout may be secondary to Kv1.3 hypomorph in neurons.
To address this possibility, we used a chemical biology approach, as in neurons Kv1.3 is typically part of hetereomultimers with Kv1.1, Kv1.2 and Kv1.6 subunits (Helms et al., 1997) (Schmitz et al., 2005 ) that selectively targets homotetrameric Kv1.3 channels which are most commonly found on immune cells (Feske et al., 2015) . PAP-1 inhibits Kv1.3 with an IC 50 of 2 nM (Schmitz et al., 2005) , has a half-life of 3 hr in rodents, is orally available, brain penetrant and does not exhibit any long-term toxicity in rodents or primates (Azam et al., 2007; Beeton et al., 2006; Pereira et al., 2007) . We administered PAP-1 (40 mg/kg) by intraperitoneal injection at one hour after ICV-LPS and retrieved the brain for study at 24 hr. Similar to Kv1.3 knockout, PAP-1 treatment reduced the FIG URE 6 PAP-1 treatment reduces the expression of pro-inflammatory mediators following ICV-LPS. WT mice first received ICV-PBS or ICV-LPS and 1 hr later received intraperitoneal injection of PAP-1 (40 mg/kg) or the vehicle Miglyol-812. Twenty-four hours later, the brains were bisected and used for either homogenization or acute microglia isolation. (a) ELISA quantification of IL-1b and TNF-a levels in brain homogenates of these mice showed that increased production of the two pro-inflammatory cytokines were curbed by PAP-1 treatment. (b) qPCR quantification of the RNA of indicated molecules showed increases of pro-inflammation cytokines and iNOS mRNA in microglia acutely isolated from WT mice at 24 hr after ICV-LPS. These increases were curbed by PAP-1 treatment. There are no statistical differences in all measures between PBS/PAP-1 and LPS/PAP-1 groups. Statistical analysis was performed by two-way ANOVA with Bonferroni correction for multiple comparisons. Data are presented as means 6 SEM, n 5 6/group for qPCR and n 5 5/group for ELISA studies increased cerebral levels of the pro-inflammatory cytokines IL-1b and TNF-a induced by ICV-LPS ( Figure  F6 6a). In parallel, qPCR per- To test if acute administration of PAP-1 on hippocampal slices, which allows a more direct action of the drug on microglial Kv1.3, would also rescue the LPS-induced hLTP deficit, we administered PAP-1 by continuous perfusion, from 45 min prior to LTP induction to the end of recording, to hippocampal slices from mice 24 hr after receiving ICV-LPS. This acute treatment of PAP-1 also recovered hLTP to the control level (Figure 7d,e) . However, similar to in vivo administration of PAP-1 (Figure 7a) , the LPS-induced STP deficit was not rescued. Taken together, our data suggest that LPS-stimulated microglial proinflammatory response and associated neurotoxicity require microglial Kv1.3 activity in vivo.
| DISCUSSION
Based on data obtained from both genetic knockout and pharmacological intervention, we conclude that Kv1.3 is required for microglial M1- (Rangaraju et al., 2017 ). In the current study, we stereotactically injected LPS into the ventricles (Maezawa et al., 2006) . This approach eliminates the confounding involvement of peripheral macrophages or lymphocytes as well as the disruption of the bloodbrain barrier seen with peripheral LPS injection or in stroke models (Chen et al., 2016) , thus allowing a better assessment of the direct effect of LPS on microglia in vivo. Moreover, we verified the identity and functional expression of microglial Kv1.3 based on its signature biophysical properties and its selective pharmacological inhibition by PAP-1. We found that LPS stimulation increased microglial surface Kv1.3 current density (Figure 1) , which is likely in part due to increased Kv1.3 transcript levels (Figure 2d ). The Kv1.3 enhancement was much more robust in cortical microglia than in hippocampal microglia, supporting the location-dependent heterogeneity of microglia properties McCarthy, 2017) . Furthermore, both genetic knockout (Figures 3-5 ) and pharmacological inhibition (Figures 6 and 7 Figure   2d ), reflecting an altered reactivity. In contrast to WT microglia, Kv1.3KO microglia showed a significant increase in Kir2.1 currents as well as RNA expression following ICV-LPS. This, in combination with a study implicating Kir2.1 activity in microglia under "resting" and "antiinflammatory states" (Lam & Schlichter, 2015) , our previous observation that Kir2.1 upregulation is characteristic of IL-4 (an antiinflammatory cytokine)-stimulated microglia , and a report that Kv1.3 deletion biases T cells toward an "immunosuppressive" phenotype with increased IL-10 production (Gocke et al., 2012) , suggests that Kv1.3 reduction may skew microglial activation toward a M2-like or anti-inflammatory response. Kv1.3 knockout also abolished the LPS-increased Kv1.1 expression and reversed the LPS-reduced KCa3.1 expression ( Figure 2d) ; the in vivo significance of these findings awaits further studies. We previously conducted a study on a mouse ischemia/reperfusion model, in which the microglia/macrophages acutely isolated from the infarcted area were found to exhibit higher densities of K 1 currents with the biophysical and pharmacological properties of Kv1.3, KCa3.1, and Kir2.1 (Chen et al., 2016) , suggesting a mixed activation pattern following an ischemic insult to the brain. A recent article reported that neocortical microglia isolated and cultured from human epilepsy patients responded to LPS with an increase in TNF-a production but no change in KCa3.1 expression. In contrast, IL-4 slightly increased the KCa3.1 current per cell, although no significant change in channel density was observed (Blomster et al., 2016) . Thus, although previous studies using cultured neonatal microglia suggest a pro-inflammatory role of KCa3.1 (Kaushal, Koeberle, Wang, & Schlichter, 2007; Maezawa et al., 2011; Schlichter et al., 2010) , its actual functional roles in adults appear complicated and need to be verified by in vivo experiments as exemplified by this study.
It is intriguing to hypothesize that selectively blocking microglial Kv1.3 activity while preserving or even enhancing Kir2.1 activity would mitigate the neurotoxicity accompanying the pro-inflammatory activation while preserving the anti-inflammatory and tissue repair functions associated with IL-4-like effects. In this study, we used mouse hLTP as a model to test how LPS-induced M1-like microglia activation causes deterioration of neural plasticity as a form of neurotoxicity. This notion becomes particularly intriguing in view of the recent identification of LPS in adult human brains, and the reported significantly higher levels of LPS in Alzheimer's disease brains, notably in the hippocampus (Zhan et al., 2016; Zhao, Jaber, & Lukiw, 2017) . Among several inflammatory mediators produced by microglia that may detrimentally affect hLTP, the best studied are nitric oxide (NO), TNF-a, and IL-1b (Costello et al., 2011; Lynch, 2015; Wang et al., 2004) . Both Kv1.3 knockout and PAP-1 treatment effectively reduced TNF-a and IL-1b expression and production, and reduced the expression of iNOS coding for the inducible NO synthase, which in combination may underlie the complete recovery of hLTP to the normal WT levels. A significant implication of our in vivo validation, therefore, is that selective Kv1.3 blockers could be therapeutic candidates for diseases in which neurotoxic microglial activation or dysfunction is implicated, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, epilepsy, and multiple sclerosis (Wolf et al., 2017) .
We found that ICV-LPS impaired both short-term plasticity (STP) and long-term potentiation in the hippocampal Schaffer-commissural synapses ( Figure 5 and 7) . Interestingly, while both PAP-1 and Kv1.3KO mitigated LPS-induced hLTP deficit, only Kv1.3KO, but not PAP-1 mitigated LPS-induced STP deficit. This result suggests that the acute effect of LPS on STP is not likely mediated by microglial Kv1.3, as both intraperitoneal injected and bath-applied PAP-1 failed to rescue STP (Figure 7a,d) . We speculate that Kv1.3KO (or chronic Kv1.3 inhibition), but not acute inhibition of Kv1.3 by PAP-1, may cause a longlasting change of synaptic release mechanism, which endows the Schaffer collateral-CA1 synapses with resistance to LPS-mediated acute effect on the STP. Further studies are needed to clarify the mechanism.
One limitation of the current study is that, by global Kv1.3 knockout and systemic application of PAP-1, we cannot completely exclude the possible contributions of peripheral monocyte-derived macrophages and effector memory T cells, which also express Kv1.3 (Feske et al., 2015; Wulff et al., 2003) . Peripheral inhibition of Kv1.3 via our interventions may indirectly affect brain microglia, as peripheral immune modulation may impact neuroinflammation or brain function via humoral or cellular factors (Prinz & Priller, 2017; Villeda et al., 2014) . For example, heterochronic parabiosis studies showed that increasing peripheral CCL11 chemokine levels in vivo in young mice decreased adult neurogenesis and impaired learning and memory (Villeda et al., 2011) , and systemic administration of young blood plasma into aged mice improved age-related cognitive impairments (Villeda et al., 2014) . Myeloid cells and lymphocytes were also found in the newly identified meningeal lymphatics (Louveau et al., 2015) , through which the trafficking of immune cells might influence brain pathology. 
